Literature DB >> 18204841

Oxaliplatin-induced immune mediated thrombocytopenia.

Muhammad S Beg1, Rami S Komrokji, Kashif Ahmed, Malek M Safa.   

Abstract

Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18204841     DOI： 10.1007/s00280-007-0675-5

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  5 in total

1.  Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study.

Authors:  Maarten J Ten Berg; Patricia M L A van den Bemt; Sumitra Shantakumar; Dimitri Bennett; Emile E Voest; Albert Huisman; Wouter W van Solinge; Toine C G Egberts
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

Review 2.  Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.

Authors:  Marnelli A Bautista; W Tait Stevens; Chien-Shing Chen; Brian R Curtis; Richard H Aster; Chung-Tsen Hsueh
Journal:  J Hematol Oncol       Date:  2010-03-26       Impact factor: 17.388

3.  Oxaliplatin induced disseminated intravascular coagulation: A case report and review of literature.

Authors:  Shweta Kurian; Jessica Macintyre; Muzammil Mushtaq; Caio Max Rocha-Lima; Yeon Ahn
Journal:  World J Gastrointest Oncol       Date:  2012-07-15

Review 4.  Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review.

Authors:  Anthony Stack; Rashmi Khanal; Crystal S Denlinger
Journal:  Clin Colorectal Cancer       Date:  2020-07-30       Impact factor: 4.481

5.  The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer.

Authors:  Yu Fu; Xiaowan Chen; Yongxi Song; Xuanzhang Huang; Quan Chen; Xinger Lv; Peng Gao; Zhenning Wang
Journal:  BMC Cancer       Date:  2021-07-08       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.